by Annie De Groot | Feb 5, 2014 | Thinking Out Loud -Blog
Reducing Immunogenicity with DeFT Engineering EpiVax is highly trusted by drug developers at large and small biopharma world-wide. We have accurately predicted immunogenicity in humans (published) and a major portion of our success is derived from providing...
by Annie De Groot | Dec 3, 2013 | News
Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A Dreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new...
by Annie De Groot | Nov 4, 2013 | Events
EpiVax will be attending the upcoming Immunogenicity Summit in DC. EpiVax’ BDA, Anthony Marcello, will be presenting 3 posters (see below) on behalf of the EpiVax science team. Additionally, one of EpiVax’ Tregitope collaborators, Dr. David W. Scott, will...